The urinary tract infection (UTI) treatment market is estimated to be worth $11.24 billion in 2024.
According to Future Market Insights (FMI), this will grow at a compound annual growth rate of 1.9% from 2024 to 2034, growing to a valuation of $13.62 billion.
The FMI report predicts this growth to be primarily driven by the increasing incidence of UTIs and a surge in hospital visits for both testing and treatment of UTIs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze